Abstract Glioblastoma is a highly aggressive brain tumor that has a median survival of 15 months. We aim to give a substitute to the current chemotherapeutic drug temozolomide by using the FDA-approved anti-psychotic pimavanserin tartrate (PVT). To uncover the effectiveness of PVT, we did cytotoxicity assays using SRB to determine the percentage of cell survival in a dose-dependent and time-dependent manner. The apoptotic effects were measured using Annexin-V/APC assay. The mechanism of action was determined utilizing Western Blotting. In different glioblastoma tumor cell lines, the IC50 for 24 hours was between 6 µM and 10 µM. 48 and 72 hours had an IC50 between 4 µM and 6 µM. SF188 glioblastoma cell line had approximately 70% to 80% more apoptotic cells in 10 µM PVT when compared to control in Annexin-V/APC assay. PVT causes a strong modulation of the PI3K/AKT and MAPK pathways when given in increasing concentration at 48 hours. The level of apoptosis was confirmed through Western Blot as well using apoptotic markers. The preliminary data show the ability of PVT to cause apoptosis of glioblastoma tumor cells in vitro through the AKT and MAPK signaling. Citation Format: Carson Zabel, Sharavan Ramachandran, Sanjay Srivastava. Repurposing of pimavanserin tartrate for the treatment of glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1559.